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Presence of BDNF G to A SNP
P 
G (n=43) A (n=10)
Maternal demographic and clinical characteristics at enrollment (amniocentesis)
Maternal Age, years† 27 [23-33] 31 [23.75-33.25 0.459
Gravidity† 3 [2-4] 3 [2-3.25] 0.898
Parity† 1 [0-2] 1 [0.75-2] 0.426
Race‡ 0.876
Caucasian 14 (32) 4 (40)
African American 19 (44) 3 (30)
Hispanic 7 (16) 2 (20)
Other 3 (7) 1 (10)
Non-Causasian race§ 29 (67) 6 (60) 0.719
Ruptured Membranes§ 30 (70) 6 (60) 0.709
Clinical chorioamnionitis§ 3 (7) 1 (10) 0.579
Antenatal Drug treatments/exposure
Steroids§ 42 (98) 10 (100) 1.000
Antibiotics§ 40 (93) 8 (80) 0.235
Tocolysis§ 20 (47) 3 (30) 0.484
Magnesium sulfate§ 16 (37) 1 (10) 0.140
Progesterone during pregnancy§ 9 (21) 4 (40) 0.237
Pregnancy outcome characteristics
Indicated preterm delivery§ 31 (72) 4 (40) 0.071
Gestational age at delivery, weeks† 26.2 [25.1-30] 30.15 [27.43-32.7] 0.065*
Birthweight, grams† 930 [780-1450] 1460 [1114-1800] 0.099*
Apgar score at 1 minute† 6 [4-8] 6.5 [4.75-8.25] 0.646
Apgar score at 5 minutes† 8 [7-9] 8 [8-9] 0.756
1 min Apgar <7§ 22 (51) 5 (50) 1.000
5 min Apgar <7§ 8 (19) 1 (10) 1.000
Newborn male gender§ 19 (45) 3 (30) 0.488
Table B. Pre-natal maternal and peri-natal infant characteristics. Data analyzed with respect to 
presence of either the G- or the A-allele in the BDNF gene amplifi ed from venous cord blood. 
† Data analyzed by Mann Whitney Rank Sum test and presented as median [interquartile range].
‡ Data analyzed by Chi Square Analysis and presented as n (%).
§ Data analyzed by Fischer’s exact tests and presented as n (%).
* Data trending towards signifi cance (p < 0.10).
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Presence of BDNF G to A SNP P 
G (n=43) A (n=10)
Umbilical cord blood analysis
Arterial pH† 7.32 [7.29-7.35] 7.30 [7.28-7.31] 0.096*
Arterial base defi cit† 4.55 [3.05-6.08 4.8 [3.35-6.80] 0.747
Venous pH† 7.38 [7.34-7.40] 7.35 [7.33-7.39] 0.159
Venous base defi cit† 3.9 [2.1-7.25] 3.5 [1.9-8.0] 1.000
Placental histological analysis
Chorionic plate infl ammation, stages II-III§ 33 (79) 5 (50) 0.109
Amnionitis, stages 2-4§ 25 (60) 4 (40) 0.307
Choriodeciduitis, stages 2-4§ 36 (86) 7 (70) 0.349
Funisitis, stages 1-4§ 22 (52) 5 (50) 1.000
Neonatal Complications
SDF-1 T-allele§ 9 (21) 4 (40) 0.237
Innterventricular Hemorrhage§ 10 (24) 1 (11) 0.663
Brochopulmonary Dysplasia§ 7 (18) 1 (10) 1.000
Necrotizing Enterocolitis§ 5 (12) 1 (10) 1.000
Retinopathy of Prematurity§ 15 (36) 2 (22) 0.699
Periventricular Leukomalacia§ 4 (10) 1 (11) 1.000
Presumed EONS§ 28 (65) 6 (60) 1.000
Culture positive (confi rmed) EONS§ 3 (7) 3 (30) 0.077*
Clinical EONS§ 14 (33) 5 (50) 0.467
Death§ 4 (10) 0 (0) 0.576
Any Adverse Outcome§ 17 (40) 3 (30) 0.722
Table C. Post-natal clinical characteristics of the newborn infants. Data analyzed with respect to pres-
ence of either the G- or the A-allele in the BDNF gene amplifi ed from venous cord blood. 
† Data analyzed by Mann Whitney Rank Sum tests and presented as median [interquartile range].
§ Data analyzed by Fischer’s exact tests and presented as n (%).
* Data trending towards signifi cance (p < 0.10).
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Presence of SDF-1 G to A SNP
P 
G (n=40) A (n=13)
Maternal demographic and clinical characteristics at enrollment (amniocentesis)
Maternal Age, years† 29.5 [23.25-34] 25 [22.5-31.5] 0.246
Gravidity† 3 [2-4] 2 [1.5-3.5] 0.440
Parity† 1 [0-2] 1 [0-2] 0.596
Race‡ 0.165
Caucasian 11 (27.5) 7 (53.8)
African American 19 (47.5) 3 (23.1)
Hispanic 6 (15) 3 (23)
Other 4 (10) 0 (0)
Non-Causasian race§ 29 (72.5) 6 (46.15) 0.101
Ruptured Membranes§ 28 (70) 8 (61.5) 0.734
Clinical chorioamnionitis§ 3 (7.5) 1 (7.7) 1.000
Antenatal Drug treatments/exposure
Steroids§ 40 (100) 12 (92.3) 0.245
Antibiotics§ 37 (92.5) 11 (84.6) 0.586
Tocolysis§ 16 (40) 7 (53.8) 0.522
Magnesium sulfate§ 12 (30) 5 (38.5) 0.734
Progesterone during pregnancy§ 10 (25) 3 (23.1) 1.000
Pregnancy outcome characteristics
Indicated preterm delivery§ 26 (65) 9 (69.2) 1.000
Gestational age at delivery, weeks† 26.8 [25.3-30.2] 26.2 [25.1-33.2] 0.764
Birthweight, grams† 1025 [785-1487.5] 920 [805-2000] 0.577
Apgar score at 1 minute† 6 [4-8] 8 [3.5-8.5] 0.699
Apgar score at 5 minutes† 8 [7-9] 8 [6.5-9] 0.811
1 min Apgar <7§ 21 (52.5) 6 (46.2) 0.757
5 min Apgar <7§ 6 (15) 3 (23) 0.672
Newborn male gender§ 17 (42.5) 5 (41.7) 1.000
Table D. Pre-natal maternal and peri-natal infant characteristics. Data analyzed with respect to 
presence of either the G- or the A-allele in the SDF-1 gene amplifi ed from venous cord blood. 
† Data analyzed by Mann Whitney Rank Sum test and presented as median [interquartile range].
‡ Data analyzed by Chi Square Analysis and presented as n (%).
§ Data analyzed by Fischer’s exact tests and presented as n (%).
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Presence of SDF-1 G to A SNP
P 
G (n=40) A (n=13)
Umbilical cord blood analysis
Arterial pH† 7.315 [7.293-7.350] 7.31 [7.285-7.327] 0.449
Arterial base defi cit† 4.2 [3.05-6.05] 5.1 [3.325-6.825] 0.683
Venous pH† 7.365 [7.338-7.40] 7.380 [7.367-7.39] 0.406
Venous base defi cit† 3.9 [1.9-7.8] 3.45 [2.3-5.25] 0.688
Placental histological analysis
Chorionic plate infl ammation, stages II-III§ 31 (79.5) 7 (53.8) 0.086*
Amnionitis, stages 2-4§ 24 (61.5) 5 (38.5) 0.201
Choriodeciduitis, stages 2-4§ 35 (89.7) 8 (61.5) 0.033**
Funisitis, stages 1-4§ 22 (56.4) 5 (38.5) 0.343
Neonatal Complications
BDNF A-Allele§ 6 (15) 4 (30.8) 0.237
Innterventricular Hemorrhage§ 9 (22.5) 2 (18.2) 1.000
Brochopulmonary Dysplasia§ 5 (13.5) 3 (27.3) 0.361
Necrotizing Enterocolitis§ 5 (12.5) 1 (8.3) 1.000
Retinopathy of Prematurity§ 12 (30) 5 (45.5) 0.472
Periventricular Leukomalacia§ 4 (10) 1 (9.1) 1.000
Presumed EONS§ 26 (65) 8 (61.5) 1.000
Culture positive (confi rmed) EONS§ 6 (15) 0 (0) 0.316
Clinical EONS§ 18 (45) 1 (8.3) 0.037**
Death§ 3 (7.5) 1 (8.3) 1.000
Any Adverse Outcome§ 14 (35) 6 (50) 0.500
Table E. Post-natal clinical characteristics of the newborn infants. Data analyzed with respect to presence 
of either the G- or the A-allele in the SDF-1 gene amplifi ed from venous cord blood. 
† Data analyzed by Mann Whitney Rank Sum tests and presented as median [interquartile range].
§ Data analyzed by Fischer’s exact tests and presented as n (%).
* Data trending towards signifi cance (p < 0.10).






Chorionic plate infl ammation, stages II-III‡ 112.06 ± 16.62 145.08 ± 20.94 0.192
Amnionitis, stages 2-4‡ 92.54 ± 15.95 154.92 ± 21.41 0.014**
Choriodeciduitis, stages 2-4‡ 114.50 ± 15.75 140.63 ± 33.65 0.271
Funisitis, stages 1-4‡ 93.83 ± 16.14 147.14 ± 21.98 0.030**
Neonatal Complications
Presence of G196A SNP‡ 116.31 ± 15.62 110.23 ± 25.19 0.443
Innterventricular Hemorrhage‡ 109.46 ± 29.56 118.75 ± 15.0 0.379
Brochopulmonary Dysplasia‡ 69.2 ± 8.45 114.36 ± 14.89 0.079*
Necrotizing Enterocolitis‡ 74.48 ± 8.88 124.16 ± 16 0.089*
Retinopathy of Prematurity‡ 108.83 ± 16.38 122.82 ± 23.38 0.312
Periventricular Leukomalacia‡ 149.8 ± 54.08 108.3 ± 12.78 0.132
Presumed EONS‡ 104.29 ± 17.05 147.33 ± 17.7 0.089*
Culture positive (confi rmed) EONS‡ 118.16 ± 45.13 114.78 ± 13.51 0.461
Clinical EONS‡ 95.66 ± 19.78 141.33 ± 16.28 0.051*
Death‡ 183.43 ± 57.93 105.33 ± 12.63 0.027**
Any Adverse Outcome‡ 120.58 ±18.16 107.64 ± 22.27 0.329
Table F. BDNF protein expression levels. Average protein levels given with respect to presence or ab-
sence of complication. 
‡ Data analyzed by 1-tailed student t-tests and presented as mean BDNF ± SEM.
* Data trending towards signifi cance (p < 0.10).





Figure 1. Identifcation of G196A SNP in the BDNF gene. (a) Representative gel demonstrating BDNF 
PCR product. (b) Representative gel demonstrating cleavage products following digestion of PCR 
product by Afl III and PmlI restriction endonucleases. Sample heterozygous for the A-allele is marked 
with an arrow. (c) Representative trace sequence of BDNF gene homozygous for the G-allele at posi-






Figure 2. Identifcation of G801A SNP in the SDF-1 gene. (a) Representative gel demonstrating SDF-1 
PCR product. (b) Representative gel demonstrating cleavage products following digestion of PCR 
product by NciI restriction endonuclease. Samples heterozygous for the A-allele are marked with 
arrows. (c) Representative trace sequence of SDF-1 gene homozygous for the G-allele at position 801 
(arrow). (d) Representative trace sequence of the SDF-1 gene heterozygous for the A-allele at position 
801 (arrow).
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Figure 3. Average BDNF expression levels with respect to presence or absence of grade 3 or 4 intraven-
tricular hemorrhage (IVH). (a) BDNF levels in patients seperated into two groups, without regard for 
presence or absence of other co-morbidities. (b) BDNF levels in patients seperated into three groups, 
demonstrating the development of early onset neonatal sepsis (EONS) as a possible confounder for ana-
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Figure 4. Adapted with permission from [9]. P11 C57BL/6 brain homoge-
nates exhibit distinct normoxic and hypoxic selected transcription
factor and growth factor expression levels compared with CD-1 pups. 
Analysis of expression levels of (A) HIF1α, (B) BDNF, (C) VEGF, and (D) 
SDF-1 in C57BL/6 (open boxes) and CD-1 (shaded boxes) brain homog-
enates under normoxic (NX) and hypoxic (HX) conditions (vertical bars 
represent standard deviations; n = 3).
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Figure 5. Reproduced with permission from [9]. Working 
model of the signaling pathway components that are diff eren-
tially regulated in C57BL/6 and CD-1 pup brain tissues and 
cultured NPCs under normoxic and hypoxic conditions.
49
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